$LQDA

Moomaw Scott sold $682K of LQDA

Moomaw Scott (Chief Commercial Officer) sold 9,539 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.68M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moomaw Scott
Published Jul 15, 2026, 12:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Because the sale is pre-arranged under a 10b5-1 plan and lacks any accompanying corporate update, it is unlikely to change the investment thesis on its own.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information to drive repricing.

03

What to watch

The article provides sale size and price range but no context on total insider holdings, other concurrent transactions, or whether the plan was modified.

Relevance 4/10Novelty 2/10Timing: Filed July 14 after July 13 insider sale.

Background

The article is an SEC Form 4 insider transaction for Liquidia Corp, reporting an open-market sale by the Chief Commercial Officer.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia CCO Moomaw Scott sold $682,141 of LQDA shares in two open-market trades under a 10b5-1 plan on July 13.

Expected impact

Likely limited near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not include new company performance, guidance, or regulatory/clinical developments.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed operational change.

None.

None.

Counterpoint

Insider selling can sometimes precede negative developments, but this transaction is explicitly under a 10b5-1 plan, reducing interpretive value.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Moomaw Scott

    Chief Commercial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.